Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).
ASCPT Annual Meeting
Date/Time: March 22, 2023 at 5:00pm – 6:30pm EDT
Poster Title: Early Clinical PK/PD Modeling and Simulation of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, to Support Clinical Trials in Multiple Autoantibody-and/or B Cell-Related
Diseases
Poster Number: PI-059
Session Name: Poster Session I
Location: Hyatt Regency, Atlanta, Georgia, Exhibit Hall
ISN World Congress of Nephrology (WCN)
Date/Time: March 31, 2023 at 17:00 – 18:00 ICT
Poster Title: Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, & Pharmacodynamics of Povetacicept (ALPN-303), a Dual BAFF/APRIL Antagonist for the Treatment
of Autoimmune Glomerulonephritides
Poster Number: FRI-080
Location: Queen Sirikit National Convention Center, Bangkok, Thailand; Exhibit Hall, Ballroom on Level 1
About Povetacicept (ALPN-303) and the RUBY-1 Phase 1 Study
Povetacicept (ALPN-303) is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in the activation and survival of B cells, particularly antibody-secreting cells. Based upon an engineered TACI (transmembrane activator and CAML interactor) domain, povetacicept exhibits greater potency in preclinical studies versus wild-type TACI-based comparators, as well as other inhibitors of BAFF and/or APRIL alone. Povetacicept is in development for multiple B cell and/or autoantibody-related diseases, such as systemic lupus erythematosus, autoimmune glomerulonephritis, and autoimmune cytopenias.
Lesen Sie auch
RUBY-1 (NCT05034484) is a phase 1, randomized, placebo-controlled study in healthy adult volunteers designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of intravenously and subcutaneously administered povetacicept. Povetacicept was well tolerated at doses up to 960 mg, with dose-dependent pharmacokinetics and reductions in circulating immunoglobulins and antibody-secreting cells, supporting the use of a once every four-week dose regimen for subsequent studies.